224 related articles for article (PubMed ID: 3480363)
1. [A clinical evaluation of CA 125 levels in serum, ascites and pleural effusion].
Jibiki K; Demura R; Abe Y; Odagiri E; Demura H
Gan No Rinsho; 1987 Nov; 33(14):1756-62. PubMed ID: 3480363
[TBL] [Abstract][Full Text] [Related]
2. [High Ca 125 serum level in benign ascites or pleural effusion].
Mezger J; Häussinger KE; Wilmanns W; Lamerz R
Geburtshilfe Frauenheilkd; 1987 Jul; 47(7):463-5. PubMed ID: 3476336
[TBL] [Abstract][Full Text] [Related]
3. [Clinical evaluation of various tumor markers in pleural effusion and in the serum].
Jibiki K; Abe Y; Takeda M; Iwachika C; Odagiri E; Demura R; Demura H
Gan No Rinsho; 1989 Aug; 35(9):991-8. PubMed ID: 2769951
[TBL] [Abstract][Full Text] [Related]
4. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study.
Topalak O; Saygili U; Soyturk M; Karaca N; Batur Y; Uslu T; Erten O
Gynecol Oncol; 2002 Apr; 85(1):108-13. PubMed ID: 11925128
[TBL] [Abstract][Full Text] [Related]
5. [A clinical evaluation of the CA 72-4 serum level as a possible tumor marker].
Jibiki K; Takeda M; Abe H; Ito M; Odagiri E; Demura R; Demura H; Takizawa K
Gan No Rinsho; 1990 Oct; 36(12):2146-52. PubMed ID: 2232183
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum CA 125 levels in patients with benign ascitic or pleural effusions.
Mezger J; Wilmanns W; Lamerz R
Tumour Biol; 1988; 9(1):47-52. PubMed ID: 3163160
[TBL] [Abstract][Full Text] [Related]
7. [Immunochemical approach to clinical cytology by demonstration of tumor markers using enzyme-labeled antibody technic].
Nishida K; Yamamoto T; Yoshioka K; Iida M; Miyagawa H; Yoshikawa T; Sugino S; Kondo M
Gan No Rinsho; 1986 Jul; 32(8):895-9. PubMed ID: 2427754
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids.
Sevinc A; Buyukberber S; Sari R; Kiroglu Y; Turk HM; Ates M
Gynecol Oncol; 2000 May; 77(2):254-7. PubMed ID: 10785474
[TBL] [Abstract][Full Text] [Related]
9. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
[TBL] [Abstract][Full Text] [Related]
10. [Detection of gastric cancer associated antigens in ascitic and pleural fluid for ascertaining the nature of the exudate].
Zhang JR; Zhang XY; Chen XT
Zhonghua Nei Ke Za Zhi; 1989 Dec; 28(12):729-30, 768. PubMed ID: 2636090
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
Li CS; Cheng BC; Ge W; Gao JF
Int J Clin Pract; 2007 Mar; 61(3):444-8. PubMed ID: 17313612
[TBL] [Abstract][Full Text] [Related]
12. [Significance of CA 125 antigen levels in patients with ovarian cancer].
Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer.
Crombach G; Zippel HH; Würz H
Cancer Detect Prev; 1985; 8(1-2):135-9. PubMed ID: 3864535
[TBL] [Abstract][Full Text] [Related]
14. [Immunological assay of the CA-125 value in pleural effusion in various types of pleuritis--its application as a differential diagnostic parameter of tuberculous or carcinomatous pleuritis].
Mitsutake Y; Hiromatsu Y; Saisho M; Tokunaga N; Ichikawa Y; Kaji M; Irie K
Gan No Rinsho; 1986 May; 32(5):453-7. PubMed ID: 3459902
[TBL] [Abstract][Full Text] [Related]
15. [Diagnostic characteristics of the CA-50 and CA 72-4 tumor markers in body fluids. Use in the diagnosis of malignant effusions].
Lemberger J; Libman E; Lászlo-Klein M; Skenderović S; Novak A
Med Pregl; 1991; 44(3-4):126-9. PubMed ID: 1921859
[TBL] [Abstract][Full Text] [Related]
16. [Study of the mechanism of tumor marker CA125 in serum].
Kiyozuka Y; Noda T; Adachi S; Adachi S; Akada S; Ichijo M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1951-8. PubMed ID: 2592818
[TBL] [Abstract][Full Text] [Related]
17. New approaches in the diagnostic procedure of malignant pleural effusions.
Terracciano D; Di Carlo A; Papa P; Cicalese M; Maietta P; Cecere C; Mariano A; Macchia V
Oncol Rep; 2004 Jul; 12(1):79-83. PubMed ID: 15201963
[TBL] [Abstract][Full Text] [Related]
18. Elevated pleural fluid RCAS1 is a diagnostic marker and outcome predictor in lung cancer patients.
Aoe K; Hiraki A; Yamazaki K; Nakamura Y; Murakami T; Maeda T; Nishimura M; Sugi K; Ueoka H
Int J Oncol; 2006 Jul; 29(1):65-72. PubMed ID: 16773186
[TBL] [Abstract][Full Text] [Related]
19. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma.
Davidson B; Elstrand MB; McMaster MT; Berner A; Kurman RJ; Risberg B; Trope CG; Shih IeM
Gynecol Oncol; 2005 Jan; 96(1):42-7. PubMed ID: 15589578
[TBL] [Abstract][Full Text] [Related]
20. Positive effusion cytology as the initial presentation of malignancy.
Monte SA; Ehya H; Lang WR
Acta Cytol; 1987; 31(4):448-52. PubMed ID: 3604540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
